EPRX (Eupraxia Pharmaceuticals) Change In Inventory : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Eupraxia Pharmaceuticals Change In Inventory?

Eupraxia Pharmaceuticals's change in inventory for the quarter that ended in Mar. 2025 was $0.00 Mil. It means Eupraxia Pharmaceuticals's inventory stayed the same from Dec. 2024 to Mar. 2025 .

Eupraxia Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means Eupraxia Pharmaceuticals's inventory stayed the same from Dec. 2023 to Dec. 2024 .

Eupraxia Pharmaceuticals's Total Inventories for the quarter that ended in Mar. 2025 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Eupraxia Pharmaceuticals Change In Inventory Historical Data

The historical data trend for Eupraxia Pharmaceuticals's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eupraxia Pharmaceuticals Change In Inventory Chart

Eupraxia Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

Eupraxia Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Eupraxia Pharmaceuticals Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Eupraxia Pharmaceuticals (NAS:EPRX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Eupraxia Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Eupraxia Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Eupraxia Pharmaceuticals's Inventory to Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Eupraxia Pharmaceuticals Change In Inventory Related Terms

Thank you for viewing the detailed overview of Eupraxia Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Eupraxia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eupraxia Pharmaceuticals Inc (NAS:EPRX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

EPRX:Canada

Address

201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4

Website

https://www.eupraxiapharma.com

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.